Therapeutic apheresis in ANCA Associated Vasculitis: Current status of Pexivas.

Pexivas is a Randomized Control Trial launched in June 2010 – recruitment stopped in September 2016, where 704 patients with ANCA Associated Vasculitis (AAV) presenting with eGFR lower than 50 ml/min were randomized to additional PLEX (PLEX) and two steroid protocols and followed on average 2.9 years. The results were published in 2020 [ [1] Walsh M. Merkel P.A. Peh C.A. Szpirt W.M. et al. Plasma exchange and glucocorticoids in Severe ANCA Associated Vasculitis. N Engl J Med. 2020; 382: 622-631 Crossref PubMed Scopus (0) Google Scholar ].